News

News and Comment

  • 10 October 2019

    Bioelectronics ‘jump-start’ the next wave of device therapeutics

    Read more
  • 10 May 2018

    Could future nerve implants detect and monitor illness?

    Read more
  • 24 January 2018

    Delivering electricity as medicine with Kate Rosenbluth

    Read more
  • 06 December 2017

    Bioelectronic medicine is a fast growing alternative to drugs

    Read more
  • 03 May 2017

    The shock tactics set to shake up immunology

    Read more
  • 09 December 2016

    Acting on the potential of action potentials: will bioelectronic medicines be the next biologics?

    Read more
  • 01 August 2016

    GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines

    Read more
  • 11 March 2015

    GlaxoSmithKline's big bet on electroceuticals

    Read more
  • 30 June 2014

    Shock Therapy: the nascent bioelectronic medicine field will require a multidisciplinary effort to succeed

    Read more
  • 30 May 2014

    Bioelectronic medicines: a research roadmap

    Read more
  • 23 May 2014

    Can the Nervous System be Hacked?

    Read more
  • 08 August 2013

    GSK launches venture capital fund to invest in pioneering bioelectronic medicines and technologies

    Read more
  • 10 April 2013

    Drug discovery: A jump-start for electroceuticals

    Read more

Portfolio News

  • CVRx receives FDA approval for world’s first heart failure neuromodulation device

    Read more

    16 August 2019

  • SetPoint study shows significant reduction in rheumatoid arthritis symptoms. EULAR press release.

    Read more

    17 June 2019

  • Saluda Medical announces clinical study results for Evoke® ECAP-controlled, closed-loop SCS System for the treatment of chronic pain

    Read more

    03 June 2019

  • Cala Health raises $50 Million Series C funding

    Read more

    21 May 2019

  • CVRx 6-month data from the BeAT Heart Failure Study presented at HRS

    Read more

    09 May 2019

  • Neuspera Medical announces final close of $26M Series B equity financing

    Read more

    20 February 2019

  • Cala Health receives FDA clearance for Cala ONE and presents new evidence at American Academy of Neurology Annual Meeting

    Read more

    26 April 2018

  • Neuspera Medical announces initial close of $26M Series B equity financing

    Read more

    24 January 2018

  • SetPoint secures $30 Million Series D Equity financing. Funding supports clinical momentum; enables upcoming phase 2 trial in rheumatoid arthritis.

    Read more

    28 August 2017

  • Saluda Medical secures AU$53 Million in D Round funding. Latest funding will support US pivotal clinical trial and global commercialization of Evoke™, the first intelligent, closed-loop spinal cord stimulation system

    Read more

    29 May 2017

  • CVRx secures $113 Million in new financing. Equity offering to support heart failure trial was oversubscribed

    Read more

    09 August 2016

  • SetPoint's breakthrough first-in-human study shows vagus nerve stimulation significantly reduces rheumatoid arthritis symptoms, inhibits cytokine production

    Read more

    04 July 2016

  • SetPoint announces $15 Million equity financing, adds major strategic investor. Series C1 funding supports ongoing development of bioelectronic therapies

    Read more

    08 September 2015

  • SetPoint announces first trial of Bioelectronic therapy to treat Crohn's Disease. Second study in humans to evaluate bioelectronic medicine for autoimmune disease.

    Read more

    04 December 2014

  • SetPoint Medical Named One of the “Fierce 15” Leading Medical Technology Companies of 2013

    Read more

    15 October 2013

  • SetPoint Medical Secures $27 Million Financing, Adding Action Potential Venture Capital/GSK, Boston Scientific and Covidien Ventures as New Investors

    Read more

    08 August 2013